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Nonaspirin Nonsteroidal Anti-inflammatory Drugs
and Hemorrhagic Stroke Risk
The Acute Brain Bleeding Analysis Study
Nam-Kyong Choi, PhD; Byung-Joo Park, MD, PhD; Sang-Wuk Jeong, MD, PhD;
Kyung-Ho Yu, MD, PhD; Byung-Woo Yoon, MD, PhD
Background and Purpose—The relationship between nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and
hemorrhagic stroke (HS) remains unclear. We examined the risk of HS associated with the use of NANSAIDs in
Koreans.
Methods—We performed a nationwide, multicenter case-control study from 2002 to 2004. This study included 940
nontraumatic acute HS cases in patients aged 30 to 84 years, with an absence of a history of stroke or hemorrhage-prone
brain lesions, alongside 940 community controls, matched to each case by age and sex. Pretrained interviewers obtained
information on prescription drugs as well as over-the-counter drugs taken within 14 days before the onset of stroke. We
adjusted potential confounders, including family histories of stroke, histories of hypertension, smoking, alcohol
consumption, high salt intake, and laborious work hours. The adjusted ORs and their 95% CIs were calculated by
conditional logistic regression.
Results—The proportion of NANSAIDs exposure within 14 days was 2.9% for HS patients and 2.0% for the controls. The
adjusted odds ratios of stroke in NANSAIDs users compared with nonusers was 1.12 (95% CI, 0.77 to 1.65) for all HS,
1.03 (95% CI, 0.49 to 2.18) for subarachnoid hemorrhage, and 1.19 (95% CI, 0.76 to 1.87) for intracerebral hemorrhage.
Conclusions—No increased risk of HS either subarachnoid hemorrhage or intracerebral hemorrhage was found among
NANSAIDs users. (Stroke. 2008;39:845-849.)
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Substantial concerns exist over aspirin or cyclooxygenase(COX)-2 selective nonsteroidal anti-inflammatory drugs
and their relations to cardiovascular diseases. However, the
impact of nonaspirin nonsteroidal anti-inflammatory drugs
(NANSAIDs) on hemorrhagic stroke (HS) has received little
attention despite the widespread use of this therapeutic
treatment for pain, fever, and inflammation within the general
population.
Most NANSAIDs inhibit both COX-1 and COX-2.1 Like
NANSAIDs, aspirin acts as an inhibitor of COX; however,
the inhibition of platelet COX-1 by aspirin results in anti-
platelet effects associated with a reduction in thrombotic
events.2 This pharmacological mechanism might increase the
risk of HS and decrease the risk of ischemic stroke. Both
aspirin and NANSAIDs bind to the same active site on COX;2
therefore, NANSAIDs could have a similar effect as aspirin
on hemorrhagic stroke.3,4
Until now, few epidemiological studies have focused on
the risk of HS in subjects using NANSAIDs. These studies
showed no associations with the use of NANSAIDs and HS.4–6
However, they assessed the information of NANSAIDs expo-
sure using self-reports5 or prescriptions databases to 1999.4,6
Accordingly, they failed to include over-the-counter (OTC)
drugs4,6 and selective COX-2 NANSAIDs.4–6 Also, they used
discharge diagnoses and proxy measures,6 and only prescrip-
tion data for current and previous uses of other medications4
for adjusting confounders. For that reason, these studies could
not adjust for the precise status of diseases, dietary habits, and
physical activity. As we know, only 1 study has assessed both
subarachnoid hemorrhage (SAH) and intracerebral hemor-
rhage (ICH),4 whereas the others only focused on the risk of
ICH.5,6 Therefore, we performed a nationwide, multicenter, and
matched case-control study in Korea to evaluate the association
of NANSAIDs use and HS risk, including SAH and ICH.
Subjects and Methods
The Acute Brain Bleeding Analysis study is a nationwide multicenter
matched case-control study designed to investigate the risk of HS
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attributable to phenylpropanolamine contained in cold remedies in
Korea.7 The cases recruited for this study came from 33 hospitals,
including 10 centers scattered regionally and covering considerable
areas of South Korea from 2002 to 2004. This study was approved by
the Institutional Review Board of every participating hospital and all
study participants provided written informed consent to participate.
Identification of Cases
HS was defined as either SAH or ICH. The diagnosis of SAH was
based on clinical symptoms via either a brain image (CT, MRI) or
evidence of xanthochromia on a lumbar puncture. ICH was diag-
nosed based on clinical symptoms and the detection of blood in the
brain parenchyma or ventricles by CT or MRI. Eligible criteria for
the patients included age ranges of 30 to 84 years, absence of a
history of stroke or hemorrhage-prone brain lesions, no causal
relationship to trauma, and the ability to communicate and complete
an interview within 30 days after the onset of the stroke.
Selection of Controls
One community control was matched to each case for sex and age
within 5 years. The controls were recruited from siblings, friends, or
neighbors of the case subject, in descending order of preference. The
eligible criteria for the controls included absence of a history of
stroke, absence of dementia or other neurological diseases, and the
ability to communicate and complete an interview within 30 days
after the onset of the stroke in the matched case.
Data Collection
Trained nurse interviewers administered structured questionnaires,
which were evaluated for feasibility by an expert panel, to all
participants. To avoid interviewer bias, the interviewers and subjects
were kept blind to the hypothesis of this study. They were informed
that the aim of this study was to investigate the effect of lifestyles
and medications on the risk of HS.
The date showing the initial symptoms of HS were used as the
index date for the cases. Each control was questioned based on the
index date of their matched case. The information on the following
risk factors was obtained from the interview for both cases and
controls: age, sex, weight, height, level of education, occupation,
smoking status, alcohol consumption, physical activity, duration of
work, sleep habits, eating habits, family history of stroke, history of
hypertension, diabetes mellitus, hyperlipidemia, heart disease, upper
respiratory tract infections within 1 month, and all medications taken
on the index date or during the 14 days before the index date.
Especially high salt intake was coded as “yes” if the subjects
answered that they liked salty food. From the quantitative history of
physical activity surveys, we obtained information on physical
activity performed in the past 6 months. Physical activity for 7
hours per week was classified as the high amount group.
We ascertained the exposure history to medications before the
index date for all prescribed or OTC dugs. We tried to obtain the
prescriptions from all of the subjects. When prescriptions were
unavailable or medications were purchased OTC without prescrip-
tion, the subjects were asked to bring in the medication packages. If
these packages were unavailable, we asked the subjects to provide
the exact name of the drug and manufacturer and select their
medications from a book containing photographs of the packages.
Definition of Drug Exposure
Exposure to NANSAIDs was defined as being exposed to NANSAIDs
within 14 days before the index date. The time window of exposure
to NANSAIDs was defined as the interval from the last exposure
date to that of the index date. We classified NANSAIDs according to
selectivity of COX. Nonselective NANSAIDs include aceclofenac,
acemetacin, diclofenac, flufenamic acid, ibuprofen, ketoprofen,
mefenamic acid, nabumetone, naproxen, piroxicam, pranoprofen,
and zaltoprofen. COX-2 preferential and selective NANSAIDs
include celecoxib, lornoxicam, meloxicam, nimesulide, rofecoxib,
and talniflumate.8
Statistical Analysis
Conditional logistic regression was used to calculate ORs and 95%
CIs for HS among users and nonusers of NANSAIDs. Initially, we
compared demographic, clinical, and behavioral features of case and
control subjects using the Pearson 2 test, Fisher exact test, or
Student t test when appropriate. Variables whose probability values
were 0.1 and clinically important were selected as potential
adjusting variables. We then selected variables with statistically
significant differences between exposed and unexposed persons
(P0.1) with clinical importance among them. Finally, the model
included family histories of stroke, histories of hypertension, smok-
ing, alcohol consumption, high salt intake, and laborious work hours
as the adjusting variables. Stratified analyses were conducted by
different exposure time windows, the classes of NANASID, and the
type of HS. Different logistic models were used according to the HS
subtype. We adjusted for family history of stroke, history of
hypertension, high salt intake, and laborious work hours for both
SAH and ICH, and added smoking for the SAH group, and alcohol
consumption for the ICH group. The unadjusted and adjusted
estimates were calculated for each subgroup. All analyses were
performed with SAS version 9.1 (SAS Institute Inc).
Results
In total, 940 HS cases and 940 controls were recruited. Of
these cases, 442 (40.7% males; age, 50.810.6 years) had
SAH and 498 (58.0% males; age, 57.111.4 years) had ICH.
Table 1 shows the characteristics of the cases and the controls
according to hemorrhagic stroke subtype.
The cases and controls were generally similar with regard
to baseline characteristics for both SAH and ICH groups,
including age, sex, body mass index, history of diabetes
mellitus, history of hyperlipidemia, history of cardiovascular
disease, arthritis status, upper respiratory tract infections
within 30 days before the index date, use or nonuse of aspirin,
and use or nonuse of antiplatelets and anticoagulants. Com-
pared with the control subjects, the case patients were more
likely to report a family history of stroke, a history of
hypertension, high salt intake, and laborious work of 7
hours per day (P0.1) for both SAH and ICH groups. Subjects
who were current smokers and current alcohol drinkers were
more likely to have SAH and ICH, respectively.
Table 2 shows the association between NANSAIDs and HS
in all of the subjects according to exposure status. Twenty-seven
patients (2.9%) with HS were NANSAID users compared with
19 (2.0%) controls, giving a crude OR of 1.18 (95% CI, 0.80
to 1.73). The adjusted OR was 1.12 (95% CI, 0.77 to 1.65)
after adjusting for potential confounders. The adjusted ORs
for HS according to prescriptions for NANSAIDs within 3 or
14 days before the index date were 1.04 (95% CI, 0.64 to
1.71) and 1.27 (95% CI, 0.70 to 2.30), respectively, compared
with nonusers. The adjusted ORs for HS using NANSAIDs
were 1.21 (95% CI, 0.79 to 1.87) for nonselective NANSAIDs
and 0.89 (95% CI, 0.40 to 2.00) for preferential or selective
COX-2 NANSAIDs.
The results of the subgroup analyses according to type of
HS are summarized in Table 3. The adjusted OR in subjects
with SAH was 1.03 (95% CI, 0.49 to 2.18), and ICH was 1.19
(95% CI, 0.76 to 1.87), which showed no statistical signifi-
cance. The ORs from the subjects after excluding all aspirin
users (36 cases and 30 controls) and their matched cases or
controls were shown to be consistent with the ORs from all of
subjects (data not shown).
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Discussion
The results of this matched case-control study show that
NANSAIDs are not a risk factor for HS, either in SAH or
ICH. The absence of an association was evident in all
separate analyses with different exposure times and different
classes of NANSAIDs.
This study supports the findings of previous epidemiolog-
ical studies,4–6 suggesting that use of NANSAIDs is not
associated with an increased risk of HS. Although the
study by Saloheimo et al9 showed use of NANSAIDs was
associated with an increased risk for ICH, the majority of
NANSAIDs users concurrently used aspirin in mainly high
doses (1225 mg/wk), which led the researchers to conclude
that the elevated risk associated with NANSAIDs use was
primarily attributable to concurrent use with aspirin.10
Most of the beneficial and harmful effects of NANSAIDs
are related to their inhibition of the COX-1 and COX-2.11
Along with the inhibition of platelet COX-1 activity, there is
a decrease in platelet aggregation, leading to reduced throm-
boembolic potential and a commensurate prolonged bleeding
time.12 The effect of aspirin on platelet COX-1 is irrevers-
ible, thus the inhibition of COX-1 by aspirin is sustained
for 10 days, the average lifespan of platelets.2,12 Like
aspirin, NANSAIDs bind rapidly to COX; however, this
binding is reversible and, therefore, short-lived in relation to
that of aspirin.2 Consequently, the thrombotic effects of
aspirin and NANSAIDs could reveal themselves differently
in HS. However, whether the apparently absent antithrom-
botic effect of NANSAIDs is attributable to the incomplete
inhibition of COX-1 or to the concomitant inhibition of
COX-2 is unknown.4
This study has several strengths. First, it was a prospective,
nationwide case-control study. All cases of HS were con-
firmed by CT, MRI, or by postmortem examination, so the
diagnostic accuracy is high. Furthermore, the neurologists
were blinded to the drug exposure information when they
evaluated all of the potential cases, according to predefined
criteria. Although most previous studies have only assessed






N (%) of Cases
(n442)
N (%) of Controls
(n442)
N (%) of Cases
(n498)
N (%) of Controls
(n498)
Age (yr, meanSD)¶ 50.810.6 50.110.8 0.30 57.111.4 56.111.7 0.18
Male¶ 180 (40.7) 180 (40.7) 1.00 289 (58.0) 289 (58.0) 1.00
Body mass index (kg/m2, meanSD) 23.52.9 23.52.7 0.69 23.73.2 23.52.9 0.38
Family history of stroke§ 97 (21.9) 67 (15.2) 0.01 127 (25.5) 85 (17.1) 0.01
History of hypertension§ 143 (32.4) 62 (14.0) 0.01 299 (60.0) 98 (19.7) 0.01
History of diabetes mellitus 22 (5.0) 16 (3.6) 0.32 47 (9.4) 42 (8.4) 0.58
History of hyperlipidemia 14 (3.2) 18 (4.1) 0.47 17 (3.4) 27 (5.4) 0.12
History of cardiovascular disease 13 (2.9) 8 (1.8) 0.27 14 (2.8) 18 (3.6) 0.47
History of arthritis 30 (6.8) 28 (6.3) 0.79 37 (7.4) 42 (8.4) 0.56
Upper respiratory tract infections within 30
days before index date
61 (13.8) 46 (10.4) 0.12 82 (16.5) 85 (17.1) 0.80
Prescription for aspirin† 7 (1.6) 10 (2.3) 0.46 29 (5.8) 20 (4.0) 0.19
Prescription for antiplatelets and
anticoagulates‡
1 (0.2) 2 (0.5) 0.38 1 (0.2) 3 (0.6) 0.25
Smoking§ 0.01 0.22
Never smoked 253 (57.2) 291 (65.8) 259 (52.0) 250 (50.2)
Former smoker 30 (6.8) 41 (9.3) 89 (17.9) 78 (15.7)
Current smoker 158 (35.7) 107 (24.2) 149 (29.9) 165 (33.1)
Unknown 1 (0.2) 3 (0.7) 1 (0.2) 5 (1.0)
Alcohol drinking§ 0.23 0.08
Never drank 189 (42.8) 199 (45.0) 177 (35.5) 212 (42.6)
Former drinker 13 (2.9) 19 (4.3) 27 (5.4) 32 (6.4)
Current drinker 238 (53.8) 218 (49.3) 291 (58.4) 250 (50.2)
Unknown 2 (0.5) 6 (1.4) 3 (0.6) 4 (0.8)
High salt intake§ 159 (36.0) 129 (29.2) 0.03 219 (44.0) 161 (32.3) 0.01
Laborious work hours 7 hours/day§ 137 (31.0) 105 (23.8) 0.02 143 (28.7) 115 (23.1) 0.05
*P calculated by Pearson 2 test, Fisher exact test, or Student t test, when appropriate.
†Prescription for aspirin was defined as being exposed to aspirin within 14 days before the index date.
‡Clopidogrel, cilostazol, dipyridamole, ticlodipine, triflusal, and warfarin.
§P of characteristic was 0.1 when all the cases were compared with all the controls.
¶Matching variables.
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the risk of ICH,5,6,9 we compared the ORs in the specific
subgroups of HS, both ICH and SAH.
Furthermore, we collected drug exposure data directly
from our study participants. This made it possible to record
prescribed as well as nonprescribed OTC NANSAIDs. Pre-
vious studies were limited in their obtainment of information
on OTC NANSAIDs,4,6 which means that the presumptive
unexposed group may have included those actually exposed
to NANSAIDs. Such misclassification of users as nonusers of
NANSAIDs would tend to bias the estimates of NANSAID
effects toward the null.13 We minimized interviewer bias by
blinding interviewers from the research hypothesis. In addi-
tion, before starting the Acute Brain Bleeding Analysis study,
a pilot study was conducted to examine the feasibility to
confirm items and the order of questionnaire.7
In our study, several risk factors, such as family histories of
stroke, history of hypertension, smoking, alcohol consump-
tion, high salt intake, and laborious work hours, associated
with HS, were included in the multivariate analysis. Family
history of stroke is a risk factor associated with HS.14 Hyper-
tension is also a well-established independent risk factor for both
ICH and SAH.15,16 With regard to salt intake and hypertension,
many well-designed cross-sectional and longitudinal observa-
tional studies have reported that salt intake may increase blood
pressure or contribute to hypertension.17–20 Also, physical activ-
ity may modify hypertension for HS and directly lower stroke
risk as well.21 Recent meta-analysis showed moderate and high
levels of physical activity were associated with reduced risks of
HS.21,22 Smoking and alcohol drinking are known risk factors for
ICH and SAH.23–27 We adjusted all of these risk factors in our
statistical analysis.
However, these results must be interpreted in light of
some limitations. First, this study presented a lower rate of
NANSAIDs exposure than other studies.4–6 The problem
could decrease the power of this study. This difference was
caused by the definitions of current NANSAIDs users. Some
of the other studies labeled current NANSAIDs users even if
the subject’s prescription lasted until the index date or ended
within 30 days before the index date.4,6 However, we defined
exposure to NANSAIDs as being exposed to NANSAIDs
within 14 days before the index date. Second, we included
patients who were hospitalized and had the mental capacity
for responding to a direct interview to avoid information bias
from proxy interviewers. In this regard, we included those
Table 2. Association Between NANSAIDs and Risk of Hemorrhagic Stroke
Cases (n940) Controls (n940) Unadjusted OR 95% CI Adjusted OR* 95% CI
Variables
Exposure to NANSAIDs†
No 913 921 1 1
Yes 27 19 1.18 0.80–1.73 1.12 0.77–1.65
Time window of exposure to NANSAIDs‡
Never use 913 921 1 1
4–14 days 11 4 1.47 0.81–2.67 1.27 0.70–2.30
3 days 16 15 1.04 0.63–1.70 1.04 0.64–1.71
Classes of NANSAIDs
Never use 913 921 1 1
Nonselective NANSAIDs§ 21 12 1.28 0.83–1.97 1.21 0.79–1.87
Preferential or selective COX-2
NANSAIDs¶
6 7 0.93 0.42–2.07 0.89 0.40–2.00
*Adjusted for a family history of stroke, history of hypertension, smoking, alcohol consumption, high salt intake, and laborious work hours.
†Exposure to NANSAIDs was defined as being exposed to NANSAIDs within 14 days before the index date.
‡Time window of exposure to NANSAIDs was defined as the interval from the last exposure date to the index date.
§Aceclofenac, acemetacin, diclofenac, flufenamic acid, ibuprofen, ketoprofen, mefenamic acid, nabumetone, naproxen, piroxicam, pranoprofen, and zaltoprofen.
¶Celecoxib, rofecoxib, lornoxicam, meloxicam, nimesulide, and talniflumate.
Table 3. Association Between NANSAIDs and the Risk of Hemorrhagic Stroke According to Hemorrhagic Stroke
Subtype
Type of Hemorrhagic Stroke Cases Controls Unadjusted OR 95% CI Adjusted OR 95% CI
Subarachnoid hemorrhage (n442) (n442)
No exposure 435 434 1 1
Exposure to NANSAIDs‡ 7 8 0.93 0.44–1.97 1.03* 0.49–2.18
Intracerebral hemorrhage (n498) (n498)
No exposure 478 487 1 1
Exposure to NANSAIDs‡ 20 11 1.30 0.83–2.04 1.19† 0.76–1.87
*Adjusted for family history of stroke, history of hypertension, smoking, high salt intake, and laborious work hours.
†Adjusted for family history of stroke, history of hypertension, alcohol consumption, high salt intake, and laborious work hours.
‡Exposure to NANSAIDs was defined as being exposed to NANSAIDs within 14 days before the index date.
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patients with milder strokes but may have overlooked patients
with severe neurological deficits or those who died before
they had reached a hospital. Thus, the study participants were
not representative of all HS patients. Therefore, our findings
do not apply to all HS patients, particularly those having
severe or fatal neurological statuses. Third, we collected our
information about potential confounders and drug exposure
after the onset of HS. This recall bias might have affected the
results; therefore, to minimize this effect, we kept the
interviewers and participants blind to the major hypothesis of
this study. The information on OTC NANSAIDs use from
pharmacies was collected by depending on the participants’
memories. Packages of major NANSAIDs were used to aid
subjects’ recall of the brand names but failed to cover all of
the NANSAIDs in the market. However, we included many
kinds of frequently used OTC NANSAIDs packages and the
effect of missing OTC drugs used is likely small within our
study. In conclusion, we found the use of NANSAIDs does
not increase the risk of HS, either SAH or ICH.
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